Regulatory Novartis receives European Commission approval for Itvisma for spinal muscular atrophy PharmaTimesEC backs first gene replacement therapy for broad sma populationRare DiseaseRead full story pharminent July 2, 2026 (Last updated: July 3, 2026) PharmaTimes EC backs first gene replacement therapy for broad sma population Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AZ forges ever-closer ties with China’s CSPC PharmaNext: Biogen Bets on Tau at AAIC: Diranersen Phase 2 CELIA Data Related Stories Regulatory Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program pharminent July 1, 2026 Regulatory Sarepta secures early 2027 FDA decision for Duchenne drugs, pushing past confirmatory fail pharminent July 1, 2026 Regulatory FDA clears Orca’s cell therapy Tregzi for GvHD pharminent July 1, 2026
